ResMed Inc. (NYSE:RMD) insider James Hollingshead sold 7,019 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $84.16, for a total value of $590,719.04. Following the transaction, the insider now directly owns 66,409 shares in the company, valued at $5,588,981.44. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of ResMed Inc. (NYSE:RMD) opened at $85.11 on Friday. The stock has a market capitalization of $12,100.15, a price-to-earnings ratio of 29.71, a P/E/G ratio of 1.89 and a beta of 0.79. ResMed Inc. has a one year low of $58.53 and a one year high of $87.81. The company has a quick ratio of 3.86, a current ratio of 4.72 and a debt-to-equity ratio of 0.50.

ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.66. The business had revenue of $523.66 million during the quarter, compared to the consensus estimate of $506.08 million. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.62 EPS. equities analysts predict that ResMed Inc. will post 3 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 14th. Investors of record on Thursday, November 9th will be paid a $0.35 dividend. The ex-dividend date is Wednesday, November 8th. This represents a $1.40 annualized dividend and a yield of 1.64%. ResMed’s dividend payout ratio (DPR) is presently 56.68%.

A number of research analysts recently weighed in on the company. J P Morgan Chase & Co boosted their target price on ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a report on Monday, October 30th. Zacks Investment Research raised ResMed from a “sell” rating to a “hold” rating in a report on Monday, October 30th. Needham & Company LLC reissued a “sell” rating on shares of ResMed in a report on Friday, September 8th. Northland Securities restated a “sell” rating and issued a $55.00 price target on shares of ResMed in a research note on Friday, October 27th. Finally, Barclays PLC boosted their price target on ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a research note on Friday, October 27th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $67.57.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RMD. Dimensional Fund Advisors LP lifted its position in shares of ResMed by 3.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 376,787 shares of the medical equipment provider’s stock valued at $27,116,000 after acquiring an additional 12,601 shares during the period. Creative Planning lifted its position in shares of ResMed by 97.1% during the 2nd quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock valued at $130,000 after acquiring an additional 823 shares during the period. Aperio Group LLC lifted its position in shares of ResMed by 11.4% during the 2nd quarter. Aperio Group LLC now owns 57,911 shares of the medical equipment provider’s stock valued at $4,510,000 after acquiring an additional 5,949 shares during the period. State Treasurer State of Michigan lifted its position in shares of ResMed by 1.6% during the 2nd quarter. State Treasurer State of Michigan now owns 58,500 shares of the medical equipment provider’s stock valued at $4,555,000 after acquiring an additional 900 shares during the period. Finally, BB&T Corp lifted its position in shares of ResMed by 71.6% during the 2nd quarter. BB&T Corp now owns 49,519 shares of the medical equipment provider’s stock valued at $3,857,000 after acquiring an additional 20,667 shares during the period. Institutional investors and hedge funds own 60.38% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ResMed Inc. (RMD) Insider Sells $590,719.04 in Stock” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/resmed-inc-rmd-insider-sells-590719-04-in-stock/1725396.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.